Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Section of Nephrology, Boston Medical Center, Boston, MA, USA.
Nat Commun. 2024 Aug 27;15(1):7368. doi: 10.1038/s41467-024-51304-x.
The kidney tubules constitute two-thirds of the cells of the kidney and account for the majority of the organ's metabolic energy expenditure. Acute tubular injury (ATI) is observed across various types of kidney diseases and may significantly contribute to progression to kidney failure. Non-invasive biomarkers of ATI may allow for early detection and drug development. Using the SomaScan proteomics platform on 434 patients with biopsy-confirmed kidney disease, we here identify plasma biomarkers associated with ATI severity. We employ regional transcriptomics and proteomics, single-cell RNA sequencing, and pathway analysis to explore biomarker protein and gene expression and enriched biological pathways. Additionally, we examine ATI biomarker associations with acute kidney injury (AKI) in the Kidney Precision Medicine Project (KPMP) (n = 44), the Atherosclerosis Risk in Communities (ARIC) study (n = 4610), and the COVID-19 Host Response and Clinical Outcomes (CHROME) study (n = 268). Our findings indicate 156 plasma proteins significantly linked to ATI with osteopontin, macrophage mannose receptor 1, and tenascin C showing the strongest associations. Pathway analysis highlight immune regulation and organelle stress responses in ATI pathogenesis.
肾小管构成肾脏的三分之二的细胞,并占器官代谢能量消耗的大部分。急性肾小管损伤(ATI)可见于各种类型的肾脏疾病,并可能显著导致肾功能衰竭的进展。ATI 的非侵入性生物标志物可实现早期检测和药物开发。我们使用 SomaScan 蛋白质组学平台在 434 名经活检证实的肾脏疾病患者中进行检测,确定了与 ATI 严重程度相关的血浆生物标志物。我们采用区域转录组学和蛋白质组学、单细胞 RNA 测序和途径分析来探索生物标志物蛋白和基因表达以及丰富的生物学途径。此外,我们还在肾脏精准医学项目 (KPMP)(n=44)、动脉粥样硬化风险社区 (ARIC) 研究(n=4610)和 COVID-19 宿主反应和临床结果 (CHROME) 研究(n=268)中检查了 ATI 生物标志物与急性肾损伤 (AKI) 的关联。我们的研究结果表明,有 156 种血浆蛋白与 ATI 显著相关,其中骨桥蛋白、巨噬细胞甘露糖受体 1 和腱糖蛋白 C 与 ATI 的关联最强。途径分析强调了免疫调节和细胞器应激反应在 ATI 发病机制中的作用。